MA’s ZEPHYR Phase 2 trial in schizophrenia Last patient visit completed for ML-004’s IRIS Phase 2 trial in autism spectrum disorderTopline results from both Phase 2 trials expected by mid-August 2026 ...
Scientists have unveiled a breakthrough imaging method that can capture the hidden details of events unfolding in trillionths ...
Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...
This manuscript presents important findings that challenge traditional models of speech processing by demonstrating that theta-gamma phase-amplitude coupling in the auditory cortex is primarily a ...
An independent international safety monitoring board has given the ENIGMA-TRS 1 trial the go-ahead to continue as planned.
A novel imaging method captures ultrafast events with unprecedented detail by combining laser encoding and AI reconstruction. Researchers have introduced a new imaging method that reveals far more ...
Kestrel Therapeutics Inc. (“Kestrel” or the “Company”), a clinical stage biotechnology company developing next-generation ...
Satralizumab is safe and effective for patients with myelin oligodendrocyte glycoprotein antibody-associated disease, the new ...
The MMA was a hybrid measurement system developed by Polytec in the early twenty-first century. Stroboscopic video microscopy ...
Fluoride-doped perovskite nanocrystal glass reaches record blue quantum yield and enables 20,000 PPI holographic displays ...
In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by licensing a drug for the rare genetic disorder Fragile X syndrome (FXS) from ...
A fluoride-assisted strategy improves perovskite nanocrystals embedded in glass, enabling stable, high-efficiency full-spectrum emission, including record blue performance. The material supports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results